New drug cocktail shows promise for advanced kidney cancer
NCT ID NCT05899049
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding belzutifan or quavonlimab to a standard immunotherapy (pembrolizumab) and targeted therapy (lenvatinib) works better for advanced clear cell kidney cancer. About 249 Chinese patients who haven't had prior treatment will be randomly assigned to one of three drug combinations. The study measures how long patients live without their cancer worsening and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab, belzutifan, lenvatinib, and quavonlimab
What this could lead to
If successful, this could offer a more effective first-line treatment option for advanced kidney cancer, potentially extending life and delaying disease progression.
What could go wrong
This is an early-stage Phase 3 trial with a small sample size (249 participants) and focuses only on Chinese patients, so results may not apply to other populations. Drug combinations also carry risks of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000)
Beijing, Beijing Municipality, 100142, China
-
Chongqing University Cancer Hospital ( Site 6009)
Chongqing, Chongqing Municipality, 400030, China
-
Guangzhou First People's Hospital ( Site 6007)
Guangzhou, Guangdong, 510180, China
-
Henan Cancer Hospital-Urology ( Site 6006)
Zhengzhou, Henan, 450008, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S
Nanjing, Jiangsu, 210000, China
-
Ningbo First Hospital-Urology ( Site 6028)
Ningbo, Zhejiang, 315010, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003)
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036)
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Nanchang University ( Site 6019)
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 6021)
Wenzhou, Zhejiang, 325000, China
-
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 6014)
Xi'an, Shaanxi, 710061, China
-
The First Affiliated Hospital, Zhejiang University ( Site 6024)
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of Jiaxing ( Site 6033)
Jiaxing, Zhejiang, 314001, China
-
The Second Affiliated Hospital of Soochow University-Urology ( Site 6025)
Suzhou, Jiangsu, 215004, China
-
The Second Hospital of Tianjin Medical University ( Site 6032)
Tianjin, Tianjin Municipality, 300211, China
-
West China Hospital Sichuan University-Urology Surgery ( Site 6016)
Chengdu, Sichuan, 610041, China
-
Wuhan Union Hospital ( Site 6002)
Wuhan, Hubei, 430022, China